MaxCyte, Inc. Increase to Block Listing (5100M)
January 21 2021 - 9:49AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Increase to Block Listing,
Block Listing Return
and
Total Voting Rights
MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and
life sciences company, announces that application has been made for
admission to trading on AIM in respect of an additional block
listing of 942,900 common stock of $0.01 each in the capital of the
Company ("Common Stock") to become effective on 27 January
2021.
The Common Stock may be issued pursuant to the exercise of share
options under the Company's Long-Term Incentive Plan (the "LTIP")
and will, upon issue, rank pari passu in all respects with the
Company's existing Common Stock. Following this increase, the total
Block Listing will consist of 1,000,000 Common Stock.
AIM Block Admission Return
MaxCyte also makes the following update on its block listings,
pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies.
a. Name of company
MaxCyte, Inc.
b. Name of scheme(s)
MaxCyte Long Term Incentive Plan
c. Period of return:
From: 1 July 2020 To: 21 January 2021
d. Number and class of securities not issued under scheme
319,263 ordinary shares of common stock of $0.01 each
e. Number of shares issued under scheme during period
262,163 ordinary shares of common stock of $0.01 each
f. Balance under the scheme not yet issued at the end of the
period.
57,100 ordinary shares of common stock of $0.01 each
g. Number and class of share(s) (amount of stock / debt
securities) originally listed and the date of admission; If
additional block listing application have been made, under this
scheme, since the original listing application please also state
the number of shares and the date(s) of admission.
1,000,000 ordinary shares of common stock of $0.01 each on 5 May
2017
Please confirm your total issued share capital as at the end of
this period.
(If you hold any shares in Treasury state the figure
separately);
The total issued stock capital of the Company is 77,422,169
shares of Common Stock. Shareholders in the Company may use this
figure as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 67,522,080 and the number of restricted shares
of Common Stock trading under the symbol 'MXCS' is 9,900,089 .
Treasury shares (if applicable) .........Nil.............
h. Contact name and telephone number for queries;
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer
+1 301 944 1660
Date
21 January 2021
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRPPUMCGUPGGCG
(END) Dow Jones Newswires
January 21, 2021 09:49 ET (14:49 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024